Across the large outcome trials, separation of the Kaplan–Meier curves for the primary composite of cardiovascular death or HF hospitalization typically emerged within the first 30–60 days after randomization, indicating an early prognostic benefit of SGLT2 inhibition [24,25,26,27,28]. This evidence concerns the gene SLC5A2 and hydrops fetalis.